BCL2 like 1 (BCL2L1)

BCL2 like 1 (BCL2L1) encodes a key member of the Bcl-2 protein family that controls the intrinsic (mitochondrial) pathway of apoptosis by regulating mitochondrial outer membrane permeability. Through alternative splicing, it produces two major isoforms: Bcl-xL (long, anti-apoptotic) and Bcl-xS (short, pro-apoptotic). Bcl-xL acts as a potent inhibitor of cell death by sequestering pro-apoptotic factors such as BAX and BAK, blocking caspase activation, and preventing cytochrome C release from mitochondria. Its expression is often dysregulated in cancers, contributing to tumor cell survival and resistance to chemotherapy; as such, BCL2L1/Bcl-xL is a major therapeutic target for small molecule inhibitors that aim to restore apoptotic sensitivity in malignant cells. Structurally, Bcl-xL contains several Bcl-2 homology domains (BH1-3) that enable protein-protein interactions critical for its regulatory function. The protein localizes to the outer mitochondrial membrane, interacting with VDAC and other apoptosis regulators. Bcl-xL is also involved in regulating cell cycle progression and other mitochondrial functions, including metabolism and synaptic activity. Targeting BCL2L1 carries significant safety concerns, notably thrombocytopenia, due to Bcl-xL’s essential role in platelet survival.

Other names

BCL2L1BCL-2-like protein 1BCLXBcl-xLBcl-xSBCL2Lbcl-xLbcl-xSApoptosis regulator Bcl-XBCL-XL/Sprotein phosphatase 1, regulatory subunit 52 (PPP1R52)

Bcl-xL inhibitors (e.g., navitoclax) disrupt anti-apoptotic function, restoring apoptosis sensitivity, especially in tumor cells. Pro-apoptotic splicing modulation (therapies that increase Bcl-xS/Bcl-xL ratio favor cell death).